It's not often you see a company publicly tell its own shareholders to tear up the offer letter, but that's exactly what Aurora Cannabis did on Wednesday. The Canadian cannabis producer is pushing back hard against Curaleaf's unsolicited hostile takeover bid, and it's not being subtle about it.
Aurora's board of directors has unanimously concluded that Curaleaf's offer significantly undervalues the company and puts future shareholder returns at risk. In a statement, the board advised investors to take no action, not tender their shares, and if they've already accepted the offer, to withdraw those shares immediately. The message is clear: this deal is bad for Aurora shareholders, and the board wants nothing to do with it.
The Board's Case: Why This Deal Falls Short
This wasn't a snap decision. Aurora's board formed a special committee of independent directors, brought in financial and legal advisors, and conducted a comprehensive review of the proposal. After all that due diligence, they concluded that the unsolicited takeover is not in the best interest of the business or its investors.
The board's reasoning goes beyond just saying the price is too low. They argue the offer doesn't include an appropriate control premium, which is basically the extra amount a buyer should pay to gain control of a company. Without it, Aurora shareholders would be handing over their company at a discount.
The Debt Problem: Curaleaf's $1 Billion Elephant in the Room
Here's where things get interesting. Aurora's board pointed out a stark financial contrast between the two companies: Curaleaf holds over $1 billion in debt, while Aurora is completely debt-free with roughly $149 million in cash reserves. That's not just a talking point; it's a fundamental difference in financial health.
The board went further, suggesting that Curaleaf intends to use Aurora's shareholder funds to repair its own balance sheet while acquiring Aurora's assets at a steep discount. In other words, Aurora shareholders would be bankrolling Curaleaf's cleanup while giving up their own company's value.
If the deal went through, Aurora investors would be exposed to Curaleaf's share price volatility, high-cost leverage, regulatory risks, tax uncertainties, and what the board called a "weak corporate governance structure." That's a laundry list of risks that Aurora shareholders currently don't have to worry about.
Voting Power: A Raw Deal for Aurora Shareholders
One of the most striking points in Aurora's rebuttal is about control. If the acquisition were completed, Aurora shareholders would hold a 7.7% stake in the combined entity. But here's the kicker: they'd retain just 3.2% of total voting power. That's because Curaleaf has a multi-voting share structure that gives its own shareholders outsized influence.
So not only would Aurora shareholders be giving up their company at what the board considers an undervalued price, but they'd also have almost no say in how the combined company is run. It's a double whammy that the board is clearly hoping resonates with investors.
Aurora's Standalone Pitch: We're Better Off Alone
Rather than just saying "no," Aurora's leadership is making the case that the company is better off going it alone. They point to the international medical cannabis platform they've built over several years, which features high-capacity EU-GMP manufacturing facilities. This platform, they say, is delivering record international revenues and industry-leading operating margins.
The board's argument is that handing over these assets would benefit Curaleaf at the direct expense of existing Aurora investors, who would be surrendering value just ahead of future growth. In their view, the standalone operational plan offers far superior long-term returns compared to what Curaleaf is offering.
At the time of publication on Wednesday, Aurora Cannabis shares were down 0.74% at $4.01, according to market data. The market seems to be taking the news in stride, but the real test will be whether shareholders listen to their board or see something in Curaleaf's offer that Aurora's leadership doesn't.
For now, Aurora is drawing a line in the sand. The board has spoken, and they're telling shareholders to hold firm. Whether Curaleaf comes back with a better offer or walks away remains to be seen, but one thing is clear: this isn't going to be a quiet takeover.
